| value |
{"aggregator_url":"https://www.sec.gov {"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1411685/0001628280-26-023176.txt","as_of":"2026-04-03T11:12:58.166696+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1411685/0001628280-26-023176.txt","company":"Vistagen Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1411685/0001628280-26-023176.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_1100b129e2301676","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1411685/0001628280-26-023176.txt","content_type":"text/plain","enriched_at":"2026-04-03T13:13:06.065905+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"vtgn-20260401","final_url":"https://www.sec.gov/Archives/edgar/data/1411685/0001628280-26-023176.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1411685/0001628280-26-023176.txt","source_event_id":"evt_397481582816","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"225d3d5a4bb31a28","kind":"sec_filing","published_at":"20260402","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.9,"dates_mentioned":["2026-04-01","2026-04-02"],"entities":[{"asset_class":"equity","name":"Vistagen Therapeutics, Inc.","relevance":"high","symbol":"VTGN","type":"company"}],"event_type":"regulation","information_gaps":["Details on the specific actions to regain compliance are not provided."],"key_facts":["Filing date: April 2, 2026","Form type: 8-K","Non-compliance due to Audit Committee membership reduction","Cure period for compliance is available"],"numeric_claims":[],"primary_claim":"Vistagen Therapeutics, Inc. is currently non-compliant with Nasdaq Listing Rule 5605(c)(2) after a board member's resignation.","relevance_score":0.8,"sentiment":"neutral","source_quality":"high","summary":"Vistagen Therapeutics, Inc. filed an 8-K on April 2, 2026, reporting non-compliance with Nasdaq Listing Rule 5605(c)(2) due to a reduction in the Audit Committee's membership.","topics":["SEC Filing","Nasdaq Compliance"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 Vistagen Therapeutics, Inc. \u00b7 Filed 20260402","ticker":"VTGN","tickers":["VTGN"],"title":"VTGN filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/1411685/0001628280-26-023176.txt"}... |